Harvard licenses reglemer IP to Symbiotix

Harvard Medical School granted Symbiotix Biotherapies Inc. (Boston, Mass.) exclusive rights to IP related to the glycolipid component of polysaccharide A, which is the basis of Symbiotix lead candidate SYMB-104. The IP was developed in the lab of Harvard's Dennis Kasper, who is also scientific co-founder of Symbiotix. The partners declined to provide details...